10.6084/m9.figshare.3470513.v1 Xiaoling Cai Xiaoling Cai Wenjia Yang Wenjia Yang Yifei Chen Yifei Chen Xueying Gao Xueying Gao Lingli Zhou Lingli Zhou Simin Zhang Simin Zhang Xueyao Han Xueyao Han Linong Ji Linong Ji Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis Taylor & Francis Group 2016 Age diagnosed age type 2 diabetes mellitus HbA1c 2016-07-04 16:50:45 Journal contribution https://tandf.figshare.com/articles/journal_contribution/Efficacy_of_hypoglycemic_treatment_in_type_2_diabetes_stratified_by_age_or_diagnosed_age_a_meta-analysis/3470513 <p><b>Aim</b>: To compare the effects of blood glucose lowering regimens in groups of patients categorized by baseline age and diagnosed age.</p> <p><b>Methods</b>: Placebo-controlled randomized trials in type 2 diabetes patients with a study length ≥12 weeks were included.</p> <p><b>Results:</b> A total of 246 trials were included. HbA1c changes from baseline corrected by placebo were comparable in sulfonylurea treatment between older and younger patients’ groups (weighted mean difference (WMD), –1.28% vs –0.92%, p > 0.05). Treatment with metformin between groups resulted in a comparable change in HbA1c levels (WMD, –0.97% vs –1.23%, p > 0.05). Treatment with α–glucosidase inhibitor (WMD, –0.68% vs –0.67%, p > 0.05), treatment with thiazolidinedione (WMD, –0.74% vs –1.01%, p > 0.05), treatment with DPP-4 inhibitors (WMD, –0.67% vs –0.67%, p > 0.05), and treatment with SGLT2 inhibitors (WMD, –0.54% vs –0.67%, p > 0.05) between groups also resulted in comparable HbA1c changes. Treatment with GLP-1 analogs between groups in HbA1c changes were also comparable (p > 0.05). Regression analysis indicated that the baseline age or diagnosed age was not associated with the HbA1c changes from baseline.</p> <p><b>Conclusion</b>: In each hypoglycemic treatment, the baseline age or diagnosed age was not associated with the HbA1c changes from baseline.</p>